CytomX Therapeutics
CTMX
CTMX
86 hedge funds and large institutions have $332M invested in CytomX Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
26% more funds holding
Funds holding: 68 → 86 (+18)
6.08% more ownership
Funds ownership: 46.31% → 52.39% (+6.1%)
Holders
86
Holding in Top 10
4
Calls
–
Puts
–
Top Buyers
| 1 | +$21.6M | |
| 2 | +$17.3M | |
| 3 | +$13.7M | |
| 4 |
PA
Perceptive Advisors
New York
|
+$10.5M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$5.09M |
Top Sellers
| 1 | -$22.3M | |
| 2 | -$4.99M | |
| 3 | -$3.9M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.45M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$913K |